SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Schrader AJ, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU Int 2006; 97: 4615
  • 2
    Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 237681
  • 3
    Herrmann E, Brinkmann OA, Bode ME et al. Treatment of metastatic papillary renal cell carcinoma with immunochemotherapy with interleukin-2, interferon-alpha and 5- fluorouracil. J Clin Oncol 2007; 25: Abstract 15644
  • 4
    Steiner T, Roigas J, Kirchner H et al. Clinical course of patients with metastatic papillary renal cell carcinoma. J Clin Oncol 2006; 24: Abstract 14591
  • 5
    Stadler WM, Figlin RA, Ernstoff MS et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial. Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007; 25: Abstract 5036
  • 6
    Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl 2007; 5: 300 Abstract 4506
  • 7
    Yang XJ, Tan MH, Kim HL et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005; 65: 562837
  • 8
    Mejean A, Hopirtean V, Bazin JP et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003; 170: 7647
  • 9
    Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 250512
  • 10
    Plantade A, Choueiri T, Escudier B et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. J Clin Oncol 2007; 25: Abstract 5037
  • 11
    Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC). Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25: Abstract 5010
  • 12
    Gore ME, Porta C, Oudard S et al. Safety and efficacy of sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of an expanded access trial with subpopulation analysis. Presented at the 1st European Multidisciplinary Meeting on Urological Cancers (EMUC). Barcelona 2007: Lecture O4
  • 13
    Gore ME, Szczylik C, Porta C et al. Sunitinib in metastatic renal cell carcinoma (mRCC). Preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer Suppl 2007; 5: 299 Abstract 4503
  • 14
    Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon- alpha (IFN). J Clin Oncol 2007; 25: Abstract 5033
  • 15
    Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 227181
  • 16
    Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 6570
  • 17
    Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101: 154551
  • 18
    Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17: 5238
  • 19
    Staehler M, Haseke N, Schöppler G, Stadler T, Stief CG. Sorafenib (Nexavar) beim metastasierten sarkomatoiden Nierenzellkarzinom nach Versagen einer vorangegangenen Chemotherapie mit Doxorubicin und Gemcitabine. J Urol Urogyn 2007; 14: Abstract 143
  • 20
    Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 6873
  • 21
    Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002; 168: 515
  • 22
    Linehan WM, Vasselli J, Srinivasan R et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10: 6282S9S
  • 23
    Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 216372
  • 24
    Lin ZH, Han EM, Lee ES et al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol 2004; 17: 6116
  • 25
    Wood CG. Reconstructing the cytoreductive paradigm: why timing of nephrectomy is key in era of targeted therapy. Kidney Cancer J Int 2007; 1: 1922